5 Things a cardiologist needs to know about diabetes Prof Leiter gives an update of the trials on new antihyperglycemic drugs (DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors) that have been completed or are ongoing since the FDA mandated demonstration of CV safety.
This educational video is part of a series called '5 Things a cardiologist needs to know about diabetes' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand what is important when treating patients with diabetes, and what risks these patients face.
This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.
Funding to produce this educational video series was provided by an unrestricted educational grant from MSD (USA) and Pfizer (USA).The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Kidney DiseaseA multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
Antoni Bayés-Genís, MD, PhD
Patrick Rossignol, MD, PhD
- ESC Congress 2023New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D
Amy Groenewegen, MD
- ESC Congress 2023No increase of glucose levels with bempedoic acid
Kausik Ray, MD
- ESC Congress 2023
Main messages of new ESC guidelines for CVD management in diabetes
Nikolaus Marx, MD